Halozyme Therapeutics HALO Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | $595.49M+6.9% | $557.28M+14.8% | $485.36M+9.3% | ||
| $12.93M+13.5% | $11.39M+6.1% | $10.74M+0.9% | $10.64M+0.9% | $10.54M+2.4% | ||
| $57.53M+11.6% | $51.57M+11.0% | $46.46M-0.9% | $46.87M+6.1% | $44.18M+1.8% | ||
| $677.42M+4.0% | $651.56M+6.6% | $611M+11.5% | $547.78M+8.7% | $503.86M+5.2% | ||
| $9.76M+40.0% | $6.97M-18.9% | $8.6M+21.4% | $7.08M-12.6% | $8.1M-24.3% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | -$571.1M-7.7% | -$530.14M-139% | -$221.69M-1.3% | ||
| —— | —— | $265.35M+311% | -$126M-1,177% | $11.7M+564% | ||
| $667.65M+3.6% | $644.59M+7.0% | $602.4M+11.4% | $540.69M+9.1% | $495.76M+5.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Halozyme Therapeutics generate?
- Halozyme Therapeutics (HALO) generated $677.4M in operating cash flow over the trailing twelve months.
- What is Halozyme Therapeutics's free cash flow?
- After $9.8M of capital expenditures, Halozyme Therapeutics's free cash flow was $667.7M over the trailing twelve months, up 34.7% year over year.
- Where does Halozyme Therapeutics's cash flow data come from?
- Every line is extracted from Halozyme Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
